Multiple Sclerosis and Cannabis: A Cognitive and Psychiatric Study
Neurol 71:164-169, Ghaffar,O. &Feinstein,A., 2008
The Alcohol Withdrawal Syndrome
JNNP 79:854-862, McKeon,A.,et al., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Efficacy and Safety of Oral Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase LLB Study
Lancet 372:1463-1472, Kappos,L.,et al, 2008
Multiple Sclerosis
Lancet 372:1502-1517, Compston,A. &Coles,A., 2008
Gray Matter Atrophy in Multiple Sclerosis: A Longitudinal Study
Ann Neurol 64:255-265,230, Fisher,E.,et al, 2008
Curable Cause of Paraplegia: Spinal Dural Arteriovenous Fistulae
Stroke 39:2756-2759, Aghakhani,N.,et al, 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Effect of Laquinimod on MRI-Monitored Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIb Study
Lancet 371:2085-2092,2059, Comi,G.,etc., 2008
Remission of Refractory Neurosarcoidosis Treated With Brain Radiotherapy: A Case Report and a Literature Review
The Neurologist 14:120-124, Motta,M.,et al, 2008
Stroke
Lancet 371:1612-1623, Donnan,G.A.,et al, 2008
Tick-Borne Encephalitis
Lancet 371:1861-1871, Lindquist,L. &Vapalahti,O., 2008
Mlutiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-Up
Arch Neurol 65:727-732, The Optic Neuritis Study Group, 2008
Thrombolysis in Patients With Marked Clinical Fluctuations in Neurologic Status Due to Cerebral Ischemia
Arch Neurol 65:1041-1043,1017, Ozdemir,O.,et al., 2008
Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008
Percutaneous Clot Removal Devices in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Arch Neurol 65:1024-1030, Stead,L.G.,et al., 2008
Rapidly Progressive Dementia
Ann Neurol 64:97-108, Geschwind,M.D.,et al., 2008
Effect of Demebon on Cognition, Activities of Daily Living, Behavior, and Global Function in Patients With Mild-To-Moderate Alzheimers Disease: A Randomised, Double-Blind, Placebo-Controlled Study
Lancet 372:207-215,179, Doody, R.S.,et al., 2008
Prediction of Functional Outcome in Patients With Primary Intracerebral Hemorrhage: The FUNC Score
Stroke 39:2304-2309, Rost,N.S.,et al., 2008
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Management of Patients With Head Injury
Lancet 372:685-687, Mendelow,A.D.,et al., 2008
Effect of Neurologic Complications on Outcome After Heart Transplant
Arch Neurol 65:226-231, van de Beek,D.,et al, 2008
B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008
Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008
Interferon �-Associated Retinopathy in Patients Treated for Multiple Sclerosis
Neurol 70:1153-1155, Folden,D.V.,et al, 2008
Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis
NEJM 358:647-648, Mullen,J.T.,et al, 2008
Mitoxantrone as Induction Treatment in aggressive Relapsing Remitting Multiple Sclerosis: Treatment Response Factors in a 5 Year Follow-up Observational Study of 100 Consecutive Patients
JNNP 79:52-56, Le Page,E.,et al, 2008
Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008
An Approach to the Diagnosis of Acute Transverse Myelitis
Semin Neurol 28:105-120, Jacob, A.,et al, 2008
Sarcoidosis: Clinical, Hormonal, and Magnetic Resonance Imaging (MRI) Manifestations of Hypothalamic-Pituitary Disease in 9 Patients and Review of the Literature
Medicine 86:259-268, Bihan,H.,et al, 2007
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 69:1552-1553, Sorenson,P.S. &Bertolotto,A., 2007
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
Primary Central Nervous System Vasculitis: Analysis of 101 Patients
Ann Neurol 62:442-451,430, Salvarani,C.,et al, 2007
Treatment of Physicians With Epilepsy
Neurol 69:1374-1379, Allen,J.W. &Devinsky,O., 2007
Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007
Guidelines For Using Proton MR Spectroscopy in Multicenter Clinical MS Studies
Neurol 69:1942-1952, De Stefano,N.,et al, 2007
Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007
Multifocal Motor Neuropathy: The Diagnostic Spectrum and Response to Treatment
Neurol 69:1680-1687, Slee,M.,et al, 2007
Acute Fulminant Demyelinating Disease: A Descriptive Study of 60 Patients
Arch Neurol 64:1426-1432, de Seze,J.,et al, 2007
Central Nervous System Infections in Heart Transplant Recipients
Arch Neurol 64:1715-1720, van de Beek,D.,et al, 2007
Aggressive Therapy for Neurosarcoidosis: Long-Term Follow-Up of 48 Treated Patients
Arch Neurol 64:691-696, Scott,T.F.,et al, 2007
Refractory Neurosarcoidosis Responsive to Infliximab
Pract Neurol 7:112-115, Kobylecki,C. &Shaunak,S., 2007
Electromyographic Biofeedback for the Recovery of Motor Function After Stroke
Stroke 38:1999-2000, Woodford,H.J. &Price,C., 2007
Neurologic Complications of Gastric Bypass Surgery for Morbid Obesity
Neurol 68:1843-1850, Juhasz-Pocsine,K.,et al, 2007
Wernicke Encephalopathy After Obesity Surgery: A Systematic Review
Neurol 68:807-811, Singh,S. &Kumar,A., 2007
Natalizumab Reduces Visual Loss in Patients with Relapsing Multiple Sclerosis
Neurol 68:1299-1302, Balcer,L.J.,et al, 2007
Reactivation of JC Virus and Development of PML in Patients With Multiple Sclerosis
Neurol 68:985-990, Khalili,K.,et al, 2007
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Natalizumab for Multiple Sclerosis
NEJM 356:2622-2629, Ransohoff,R.M., 2007